zolmitriptan is a selective serotonin receptor agonist of the 1b and 1d subtypes. it is a triptan, used in the acute treatment of migraine attacks with or without aura and cluster headaches. zolmitriptan is marketed by astrazeneca with the brand names zomig, zomigon (argentina, canada & greece), ascotop (germany) and zomigoro (france). in 2008, zomig generated nearly $154 million in sales. astrazeneca's u.s. patent on zomig tablets expired on november 14, 2012, and its pediatric exclusivity extension expired on may 14, 2013. the patent in certain european countries has already expired too, and generic drug maker actavis released a generic version in those countries, starting in march 2012.